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Abstract
Background Hemophilia B is an X-linked bleeding disorder that results from
a deficiency in functional coagulation factor IX (hFIX). In patients lacking
FIX, the intrinsic coagulation pathway is disrupted leading to a lifelong,
debilitating and sometimes fatal disease.
Methods We have developed an ex vivo gene therapy system using
genetically modified bone marrow stromal cells (BMSCs) as a platform for
sustained delivery of therapeutic proteins into the general circulation. This
model exploits the ability of BMSCs to form localized ectopic ossicles when
transplanted in vivo. BMSCs were transduced with MFG-hFIX, a retroviral
construct directing the expression of hFIX. The biological activity of hFIX
expressed by these cells was assessed in vitro and in vivo.
Results Transduced cells produced biologically active hFIX in vitro with a
specific activity of 90% and expressed hFIX at levels of ∼497 ng/106 cells/24 h
and 322 ng/106 cells/24 h for human and porcine cells, respectively. The
secretion of hFIX was confirmed by Western blot analysis of the conditioned
medium using a hFIX-specific antibody. Transduced BMSCs (8 × 106 cells
per animal) were transplanted within scaffolds into subcutaneous sites in
immunocompromised mice. At 1 week post-implantation, serum samples
contained hFIX at levels greater than 25 ng/ml. Circulating levels of hFIX
gradually decreased to 11.5 ng/ml at 1 month post-implantation and declined
to a stable level at 6.1 ng/ml at 4 months.
Conclusions These findings demonstrate that genetically modified BMSCs
can continuously secrete biologically active hFIX from self-contained ectopic
ossicles in vivo, and thus represent a novel delivery system for releasing
therapeutic proteins into the circulation. Copyright  2002 John Wiley &
Sons, Ltd.
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Introduction
Ex vivo gene therapy strategies utilize autologous cells that are genetically
modified prior to reimplantation [1]. In principal, this approach offers
the potential to correct a wide spectrum of inherited and acquired
human diseases. Ex vivo gene therapy methods have successfully corrected
genetic defects in patients with severe combined immunodeficiency
syndrome [2], and are also being developed to deliver therapeutic proteins
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into the circulation [3–6]. Genetically modified mes-
enchymal cells such as fibroblasts and myoblasts have
been used most frequently as vehicles to deliver recom-
binant proteins in vivo in part because they are readily
accessible and can be easily expanded in culture [7–10].
However, several other cell types are being explored as
alternative means to deliver therapeutic proteins in vivo.
For example, genetically modified hematopoietic stem
cells are effective in correcting genetic defects in animal
models [11–13], hepatocytes are capable of long-term
expression of transgenes [14–16], and neuronal cells can
deliver neurotropic factors in vivo [17,18].
Hemophilia is a class of bleeding disorders that is
actively being examined as a model for in vivo and
ex vivo gene therapy [19]. Hemophilia B is an X-
linked bleeding disorder that results from a deficiency
in functional coagulation factor IX (hFIX). In patients
lacking FIX, the intrinsic coagulation pathway is disrupted
leading to a lifelong, debilitating and sometimes fatal
disease. Treatment strategies include the infusion of
plasma-derived clotting factor concentrates and the more
currently available recombinant hFIX [20]. However,
despite these therapies, substantial financial cost and
significant morbidity result when excessive hemorrhage
occurs in joints and muscle spaces.
Cloning of the cDNA encoding hFIX has facilitated
molecular approaches to correcting the inherited defects
associated with hemophilia B [21]. Because the liver is
the normal site for FIX synthesis, it has been the target of
several gene therapy approaches for hemophilia [22,23].
Therapeutic delivery of FIX in ectopic sites has also
been studied by retroviral transduction of hematopoietic
cells [24], myocytes [7] and bone marrow stromal cells
that were reinfused into the peripheral circulation, iliac
crest marrow or spleen [25–27]. More recently, a clinical
trial of hemophilia B gene therapy using recombinant
adeno-associated virus was carried out in humans [28].
In this study, a hFIX expression vector was delivered
via injection into skeletal muscles and the results were
modestly positive in two of the three patients enrolled.
Although these approaches show some promise, each has
its limitations.
We have developed an ex vivo strategy that may
overcome some of the limitations of either parenteral or
in situ delivery of vectors to correct inherited or acquired
diseases that have deficiencies in plasma proteins. This
ex vivo gene therapy system exploits the ability of bone
marrow stromal cells (BMSCs) to form ectopic ossicles
when transplanted in vivo. We hypothesized that these
localized ossicles would serve as in vivo bioreactors and
continuously secrete hFIX into the general circulation.
BMSCs become the predominant adherent cell population
when bone marrow is cultured in vitro [29]. When
transplanted into ectopic sites within scaffolds that
support cell adhesion and differentiation, BMSCs form
self-contained, vascularized bone ossicles consisting of
bone and marrow [30–33]. Here, we demonstrate that
BMSCs genetically modified with a retrovirus engineered
to express hFIX are capable of producing biologically
active hFIX in vitro and can secrete detectable levels of
hFIX into the peripheral circulation for up to 16 weeks.
These findings demonstrate that genetically modified
BMSCs can continuously secrete biologically active hFIX
from self-contained ectopic ossicles in vivo, and thus
represent a novel delivery system for releasing therapeutic
proteins into the circulation.
Materials and methods
Vectors
Construction of the hFIX expression vector, MFG/hFIXc, is
described elsewhere [34]. This vector consists of an MFG-
type backbone and a hFIX minigene. The control virus
construct, AdRSVntlacZ, is a recombinant adenovirus that
contains the bacterial β-galactosidase gene and a nuclear
localization signal sequence [35] that was purchased from
the University of Michigan Vector Core Laboratory.
BMSC cultures
Bone marrow stromal cells were cultured from bone
marrow aspirates of human and Yucatan minipigs and
were cultured as described previously [32]. All proce-
dures were performed under University of Michigan IRB
approval. BMSCs were cultured in αMEM medium con-
taining 2 mM glutamine, 100 U/ml penicillin, 100 µg/ml
streptomycin sulfate and 10% fetal bovine serum (Life
Technologies), 10−4 M L-ascorbic acid phosphate magne-
sium salt hydrate (AscP; Wako, Osaka, Japan) and 10−8 M
dexamethasone (Dex; Sigma, St Louis, MO, USA). BMSC
strains from passages 3–5 were used for this study.
Ex vivo viral transduction
Viral stocks were produced from the Phoenix packaging
cell line as described [34]. BMSCs were cultured in 6-
well plates for 24 h (approximately 30% confluent).
The culture medium was removed and the cells
were incubated with 2 ml of virus (6.1 × 106 CFU/ml)
supplemented with Polybrene (hexadimethrine bromide,
8 µg/ml; Sigma). Following a 5-min incubation at 37 ◦C,
the culture plates were centrifuged at 2500 rpm at 32 ◦C
for 30 min and the retrovirus supernatant was replaced
by culture medium for an overnight incubation. A second
round of infection was performed as described and the
cells were cultured until confluent.
Western blot analysis
Western blot analysis using human-specific antisera was
used to confirm the secretion of hFIX. hFIX in aliquots
(1 mL) of culture medium of BMSCs was precipitated
with barium sulfate (100 mg) and subjected to Western
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Bone Marrow Stromal Cells for Gene Delivery 13
blot analysis as described previously [36]. Secreted hFIX
was detected with a rabbit anti-hFIX polyclonal antibody
and was visualized with goat anti-rabbit IgG horseradish
peroxidase conjugated secondary antibody (Bio-Rad
Laboratories) and developed using chemiluminescent
detection (Boehringer Mannheim).
Loading cells into the transplantation
vehicles
Porcine BMSCs (2 × 106 cells) were loaded into 50–
100 mm2 cube blocks of Collagraft sponges (Zimmer,
Warsaw, IN, USA) that consist of denatured bovine
type I collagen and hydroxyapatite/tricalcium phosphate
ceramic particles. After a brief centrifugation, the cell
pellets were resuspended in 30–50 ml of medium. The
Collagraft sponge was wetted with medium, compressed
between sterile filter paper to eliminate remaining air
bubbles, and immediately placed into the cell suspension
where the cells were loaded by capillary action. The
sponges containing the transduced cells were incubated
at 37 ◦C for 30 min prior to transplantation.
Transplantation of BMSCs
Immunocompromised mice (N : NIH-bg-nu-xidBR, Charles
River) served as subcutaneous transplant recipients
to avoid graft rejection of porcine BMSC transplants.
This strain of nude mice lacks T-cell function, is
devoid of natural killer cells and has poor maturation
of T-independent B-lymphocytes. Transplantation of
transduced BMSCs was performed under anesthesia
achieved by inhalation of methoxyflurane (Mallinckrodt
Veterinary, Mundelein, IL, USA). Mid-longitudinal skin
incisions of about 1 cm in length were made on the dorsal
surface of each mouse and four subcutaneous pockets
were formed by blunt dissection. A single transplant was
placed into each pocket. The incisions were closed with
surgical staples.
Evaluation of hFIX production into the
circulation
Peripheral blood was collected from excised tails of mice
with transduced BMSC transplants or non-transduced
controls and circulating hFIX determined as previously
described [37]. Following dissection of about 1 mm of
the tail, approximately 100 µl of peripheral blood samples
were collected, serum samples prepared and subjected to
quantification of circulating hFIX by a hFIX-specific ELISA.
The specific activity was also calculated using normal
human plasma as a control.
Results
Transduced BMSCs secrete biologically
active hFIX in vitro
BMSCs that were cultured from human or porcine
bone marrow aspirates were infected with MFG/hFIXc,
a retroviral construct directing the expression of hFIX.
The transduced cells from both human and porcine
origin were capable of producing biologically active
hFIX in vitro (Table 1). The transduced BMSCs secreted
biologically active hFIX with a specific activity of
90%, indicating that the overexpressed hFIX was
appropriately post-translationally modified including γ -
carboxylation [38,39]. BMSCs secreted hFIX at levels
of 497 ± 17 and 365 ± 25 ng hFIX/106 cells/24 h for
human and porcine cells, respectively, after 7 days
in culture (Table 1). Western blot analysis confirmed
that retrovirus-transduced BMSCs produced hFIX of the
expected molecular size. Immunoblots confirmed the
secretion of hFIX protein from the transduced cells
(Figure 1, lane 1), whereas no immunoreactivity was
observed in conditioned medium from non-transduced
cells (Figure 1, lane 3). hFIX secreted from BMSCs
migrated at approximately 68 kDa, a size that corresponds
to the recombinant hFIX control (Figure 1, lane 2) and to







Figure 1. Western blot analysis of hFIX secreted from
transduced porcine BMSCs in vitro. Protein samples from
conditioned medium were resolved by SDS-PAGE. Lane1,
MFG/hFIXc-transduced BMSCs; lane 2, recombinant hFIX con-
trol; lane 3, non-transduced cells. The numbers on the right
indicate the molecular size markers in kDa
Table 1. Expression of hFIX in MFG-hFIX-transduced BMSCs in vitro
Day 2 Day 3 Day 4 Day 5 Day 6 Day 7
Control (ng/106 cells/24 h) 0 0 0 0 0 0
Infected Human BMSCs (ng/106 cells/24 h) nd nd nd nd nd 497.4 ± 16.8
Infected Porcine BMSCs (ng/106 cells/24 h) 358.4 ± 18.5 360.9 ± 28.8 366.0 ± 26.6 355.8 ± 26.6 362.7 ± 20.9 365 ± 24.7
nd = not determined.
Values are the average ± the standard deviation.
n = 6 for each experimental group.
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Figure 2. Production of hFIX in mice. Porcine BMSCs were
transduced with MFG/hFIXc and were transplanted into
immunocompromised mice. Peripheral blood was collected
and the levels of hFIX secreted into the circulation from the
implanted ossicles were determined for up to 16 weeks. Filled
squares represent hFIX levels in MFG/hFIXc-transduced BMSCs.
Filled circles represent hFIX levels in mice receiving transplants
of non-transduced BMSCs (n = 6)
Factor IX expression in vivo
Self-contained bone ossicles are formed when BMSCs
are transplanted into ectopic sites within scaffolds that
support cell adhesion and differentiation [30,32,33,41].
When BMSCs harvested from transgenic mice carrying
type I procollagen reporter genes are transplanted,
continuous reporter gene activity can be detected from
differentiated cells within the transplant suggesting
that osteoblasts and osteoprogenitor cells derived from
transplanted BMSCs exist in a dynamic state within the
ectopic ossicles [32]. We took advantage of this dynamic
state to investigate the ability of transplanted BMSCs to
secrete biologically active proteins into the peripheral
circulation from these localized sites. Transduced BMSCs
(8 × 106 cells per animal) were loaded within scaffolds
and transplanted into subcutaneous spaces in immuno-
compromised mice at four sites. Using this approach,
BMSCs differentiated into self-contained, subcutaneous
ossicles by 4 weeks. We therefore tested the hypothesis
that transduced cells within the localized transplant would
continuously secrete hFIX into the general circulation.
Blood was collected from excised tails and serum samples
were prepared and analyzed for hFIX activity (Figure 2).
At 1 week post-implantation, serum samples contained
hFIX at a concentration level of 25 ng/ml as analyzed
by a human-specific ELISA. The hFIX levels in the
circulation gradually decreased to 17.5 ng/ml at 4 weeks
post-implantation and further declined to a stable level
at 6.1 ng/ml at 10–16 weeks. No hFIX was detected
in control animals. At 4 months post-transplantation,
implants were harvested and subjected to histological
analysis. All implants formed bone that was maintained at
the approximate size of the original implant (Figure 3A).
Localization of hFIX-producing cells
The tissues within an ossicle formed by transplanted
BMSCs exist as a chimera of donor and recipient
cells. Several experimental methods, such as the use
of species-specific antibodies, species-specific repetitive
DNA sequences and reverse transplantation, have demon-
strated that the bone-forming cells are of donor origin.
By similar criteria, hematopoietic cells and macrophages
originate from the recipient [32,33,42–44]. We there-
fore sought to identify the source of hFIX-producing cells
within the implant by incubating tissue sections of hFIX-
transduced BMSC transplants with human-specific, anti-
FIX anti-bodies. Positive immunostaining was observed
in osteoblasts and osteocytes in the newly formed ossi-
cle (Figure 3C) supporting the hypothesis that osteoblasts
derived from differentiating BMSC actively secrete hFIX
in vivo. In contrast, no immunoreactivity above back-
ground was seen in the tissue sections incubated with
non-immune serum (Figure 3B).
Figure 3. Localization of hFIX-secreting cells in transplants
of transduced porcine BMSCs. BMSCs were infected with
MFG/hFIXc in vitro and transplanted into immunocompro-
mised mice. After 5 weeks in vivo, transplants were harvested
and prepared for immunohistochemistry. (A) Hematoxylin- and
eosin-stained section showing newly formed bone (b). (B) Tissue
sections were incubated with non-immune serum and were
counterstained with hematoxylin. (C) Tissue sections were incu-
bated with a human-specific polyclonal antibody and were
counterstained with hematoxylin. Note the brown color of
osteoblasts (black arrowheads) demonstrating immunoreactiv-
ity to human-specific antibodies raised against hFIX. New bone
is designated b and the hydroxyapatite scaffold is designated v
(magnification 40×)
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Discussion
The objective of this study was to test the feasibility of
using genetically modified bone marrow stromal cells as
a platform for sustained systemic delivery of therapeutic
proteins into the circulation. Human factor IX served as
the model system for this study. We found that human
or porcine BMSCs could be effectively transduced with
MFG/hFIXc retrovirus and were capable of secreting
biologically active hFIX in vitro and in vivo. Consistent
with previous reports that BMSCs form bone when
transplanted within scaffolds that support cell adhesion
and differentiation, the hFIX-transduced BMSCs formed
new bone in the in vivo osteogenic assay. These self-
contained, subcutaneous ossicles were also the source of
biologically active hFIX that resulted in detectable levels
of hFIX in the peripheral circulation for up to 16 weeks.
These findings suggest that the use of BMSCs may serve as
an alternative approach to delivering therapeutic proteins
into the circulation from localized, ectopic sites.
Among the rationale for using bone marrow stromal
cells as a strategy to deliver hFIX into the circulation
is the observation that osteoblasts and hepatocytes
share some post-translational modification processes
including the vitamin-K-dependent γ -carboxylation of
specific glutamic acid residues [45]. The vitamin-K-
dependent proteins include several coagulation factors
(II, VII, IX and X), proteins C and S [39], and the
skeletal extracellular matrix proteins osteocalcin and
matrix Gla protein [46]. γ -Glytamyl carboxylase catalyzes
the post-translational modification of specific glutamic
acid residues to γ -carboxyglutamic acid (Gla) and is
required for biologic activity of the Gla proteins. In
vivo manifestation of this requirement is observed in
humans, where naturally occurring mutations in the
factor IX propeptide region occur in warfarin-sensitive
hemophilia B patients [47,48]. Therefore, our finding that
the hFIX secreted by BMSCs exhibited a specific activity
of 90% of the recombinant hFIX control demonstrates
that the transduced cells are capable of functional
post-translational modification. Because transplanted
BMSCs can differentiate into functional osteoblasts under
appropriate in vivo conditions, they are good candidates
for synthesizing biologically active proteins from ectopic
ossicles in vivo.
Hemophilia B has often been used as a model for
developing gene delivery systems. The deficiency in
plasma levels of factor IX in hemophilia B allows the
development of strategies to ectopically express the
protein in tissues such as muscle [49–52] and bone
marrow [25–27,53], in addition to the natural site of
expression in the liver [54,55]. A rather wide therapeutic
window is also an advantage for using hemophilia
B as a model for gene therapy. While circulating
levels of hormones such as insulin must be tightly
regulated to be safe and effective, the FIX plasma
concentration may be as high as 150% of the normal
median level (∼5 µg/ml plasma), although achieving
persistently high levels has been difficult. Conversely,
an increase in the FIX plasma concentration as small
as 1% of the normal level (approximately 50 ng/ml
plasma) can convert a severe form of hemophilia to
a more easily managed moderate form. Furthermore,
mouse and canine models of hemophilia B that display a
phenotype similar to hemophilia B in humans have been
generated by inactivating the FIX gene by homologous
recombination providing powerful model systems to study
the effectiveness of gene therapies [56].
Experimental models using bone marrow stromal cells
that were reinfused into the peripheral circulation, iliac
crest marrow or spleen [25–27] have been developed
as potential treatments for hemophilia. In each of these
strategies, adequate expression of coagulation factor was
dependent on engraftment of the transduced cells. The
strategy described here does not depend on proper
engraftment or homing to a particular tissue. Rather,
the transduced cells differentiate into localized ectopic
ossicles that are capable of expressing biologically active
hFIX. The levels of hFIX produced in our in vivo studies
represent near therapeutic levels for up to 2 months.
Subsequently, circulating hFIX levels declined to a
consistent level of 6 ng/ml for the duration of the study
(Figure 2). The reasons for the lack of persistent high-
level hFIX secretion are not yet understood. Potential
factors include the self-inactivation of the viral promoter,
the failure to transduce mesenchymal stem cells within
the heterogeneous BMSC population, and the failure of
fully differentiated osteoblasts within the ectopic ossicle
to continuously secrete hFIX.
Our findings demonstrate that genetically modified
BMSCs can continuously secrete hFIX from subcutaneous
sites in vivo and thus represent a novel delivery system
for releasing therapeutic proteins into the circulation. By
titrating the number of transplanted cells, this ex vivo gene
delivery system may provide better control of the number
of cells expressing a transgene than does parenteral
delivery of virus. This system may also be amenable to
the use of inducible promoters to gain additional control
of secretion. Other advantages of this new gene delivery
approach in developing gene therapies for disorders such
as hemophilia include: (1) the continuous delivery of
transgene products by targeting mesenchymal stem cells
for gene transfer, (2) avoidance of the difficulty in BMSCs
homing to the bone marrow, and (3) the ability to retrieve
the localized transplant in the event of encountering
adverse effects due to them.
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